In this study, we employed atezolizumab, an anti-PD-L1 monoclonal antibody, to investigate the therapeutic impact of combining CRTC1 modulation with PD-L1 blockade in NSCLC xenografts. The gene discussed is CRTC1; the disease is non-small cell lung carcinoma.